By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

University of Iowa et al. v. Amgen, Inc. et al.
3:08-cv-00112; filed September 8, 2008 in the Southern District of Iowa

Infringement of U.S. Patent Nos. 5,168,062 ("Transfer Vectors and Microorganisms Containing Human Cytomegalovirus Immediate-Early Promoter-Regulatory DNA Sequence," issued December 1, 1992) and 5,285,839 based on Amgen’s manufacture and sale of Enbrel® and Vectibix® (etanercept, used to treat arthritis, and panitumumab, used to treat colon cancer, respectively).  View the complaint here.  [Ed.:  As noted by a Patent Docs reader, while the complaint lists U.S. Patent No. 5,285,839 ("Internal combustion engine and method for making same"), plaintiffs likely intended to list U.S. Patent No. 5,385,839 ("Transfer Vectors and Microorganisms Containing Human Cytomegalovirus Immediate-Early Promoter-Regulatory DNA Sequence," issued January 31, 1995) instead.]

Ortho-McNeil Janssen Pharmaceuticals, Inc. v. Amneal Pharmaceuticals
2:08-cv-04494; filed September 5, 2008 in the District Court of New Jersey

Infringement of U.S. Patent No. RE39,221 ("Composition Comprising a Tramadol Material and Acetaminophen and Its Use," issued August 1, 2006) following a Paragraph IV certification as part of Amneal’s filing of an ANDA to manufacture a generic version of Ortho-McNeil’s Ultracet® (tramadol hydrochloride and acetaminophen, used to treat acute pain).  View the complaint here.